QURE

uniQure N.V. [QURE] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

QURE Stock Summary

Top 10 Correlated ETFs

QURE


Top 10 Correlated Stocks

QURE


In the News

09:20 16 Apr 2024 QURE

UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates

UniQure (QURE) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to earnings of $0.15 per share a year ago.

10:31 16 Apr 2024 QURE

3 Micro-Cap Stocks That Could Be Moonshots

Amid the valuations of large-cap stocks, notably tech stocks in the Magnificent 7 declining, this has led to this list of micro-cap stocks. Not only are investors expected to rotate into smaller and under-capitalized companies, but these companies also have unique theses that should keep investors interested.

09:46 16 Apr 2024 QURE

UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates

UniQure (QURE) came out with a quarterly loss of $1.88 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to loss of $1.02 per share a year ago.

12:47 16 Apr 2024 QURE

uniQure (QURE) Up on Restructuring Plans, Workforce Reduction

uniQure (QURE) gains on plans to discontinue investment in some projects and reduce 20% of its workforce.

01:49 16 Apr 2024 QURE

Why Shares of uniQure Are Up Thursday

uniQure said it is cutting back 28% of its workforce. The company is discontinuing much of its pipeline to focus on more promising therapies.

12:21 16 Apr 2024 QURE

uniQure slashes more than half of its research programs to preserve cash

Gene therapy-focused biotechnology firm uniQure announced it is slashing more than half of its research and technology projects as part of a strategic reorganization aimed at reducing its operating expenses while advancing a selection of its clinical-stage programs to proof-of-concept.  The company said it will no longer be investing in AMT-210 for the treatment of Parkinson's disease and multiple other undisclosed programs.

08:18 16 Apr 2024 QURE

UniQure to cut 28% of workforce and scrap more than half its research projects in strategic overhaul

UniQure N.V. QURE, -4.74%, a gene therapy company focused on developing therapies for patients with severe medical needs, said Thursday it's planning a strategic overhaul that will cut 28% of its workforce as it strives to cut costs and advance several clinical-stage programs.

01:10 16 Apr 2024 QURE

Why Shares of uniQure Are Dropping Tuesday

The Food and Drug Administration has cleared uniQure's application for an epilepsy therapy. The company grew revenue in the second quarter by 380%, year over year.

03:51 16 Apr 2024 QURE

3 Tantalizing Stocks to Buy for Under $10

As a rule of thumb, you should avoid targeting cheap securities, However, exceptions can always be made, particularly for these tantalizing stocks under $10 to buy. To be sure, the cheap ideas in the capital market attract much attention.

10:25 16 Apr 2024 QURE

UniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

UniQure (QURE) came out with a quarterly loss of $1.44 per share versus the Zacks Consensus Estimate of $2.97. This compares to loss of $0.84 per share a year ago.

QURE Financial details

Company Rating
Neutral
Market Cap
228.67M
Income
-308.48M
Revenue
15.84M
Book val./share
4.34
Cash/share
12.92
Dividend
-
Dividend %
-
Employees
480
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-1.38
Forward P/E
-1.28
PEG
-0.1
P/S
2.83
P/B
1.18
P/C
0.37
P/FCF
-1.96
Quick Ratio
9.63
Current Ratio
10.11
Debt / Equity
0.67
LT Debt / Equity
0.63
-
-
EPS (TTM)
-6.48
EPS next Y
-3.7
EPS next Q
-1.01
EPS this Y
138.75%
EPS next Y
-42.96%
EPS next 5Y
-77.03%
EPS last 5Y
15.12%
Revenue last 5Y
16.82%
Revenue Q/Q
375.41%
EPS Q/Q
-18.62%
-
-
-
-
SMA20
-
SMA50
-16.67%
SMA100
-28.57%
Inst Own
47.05%
Inst Trans
0.64%
ROA
-26%
ROE
-60%
ROC
-0.24%
Gross Margin
94%
Oper. Margin
-174%
Profit Margin
-204%
Payout
-
Shs Outstand
47.84M
Shs Float
42.55M
-
-
-
-
Target Price
53.67
52W Range
4.72-22.48
52W High
-78.52%
52W Low
+18.13%
RSI
38
Rel Volume
0.42
Avg Volume
1.03M
Volume
429.83K
Perf Week
-8.25%
Perf Month
-8.43%
Perf Quarter
-21.25%
Perf Half Y
-27.75%
-
-
-
-
Beta
0.955
-
-
Volatility
0.19%, 0.17%
Prev Close
-1.15%
Price
4.725
Change
-4.74%

QURE Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.180.8411.392.280.33
Net income per share
-3.2-2.817.17-2.71-6.47
Operating cash flow per share
-2.47-3.036.26-3.1-3.06
Free cash flow per share
-2.63-3.255.88-3.48-3.21
Cash per share
9.445.5112.17.5512.96
Book value per share
8.085.4912.9610.194.36
Tangible book value per share
7.935.410.998.382.53
Share holders equity per share
8.085.4912.9610.194.36
Interest debt per share
1.921.693.113.313.78
Market cap
2.87B1.61B953.76M1.06B322.73M
Enterprise value
2.56B1.43B533.23M974.36M219.78M
P/E ratio
-22.39-12.852.89-8.36-1.05
Price to sales ratio
393.6842.831.829.9520.37
POCF ratio
-29.05-11.923.31-7.3-2.21
PFCF ratio
-27.21-11.133.53-6.51-2.11
P/B Ratio
8.876.591.62.231.55
PTB ratio
8.876.591.62.231.55
EV to sales
351.8238.21.029.1513.87
Enterprise value over EBITDA
-23.09-12.591.68-7.27-0.87
EV to operating cash flow
-25.96-10.631.85-6.72-1.51
EV to free cash flow
-24.32-9.931.97-5.99-1.44
Earnings yield
-0.04-0.080.35-0.12-0.96
Free cash flow yield
-0.04-0.090.28-0.15-0.47
Debt to equity
0.230.290.230.30.67
Debt to assets
0.160.210.170.20.17
Net debt to EBITDA
2.751.52-1.320.640.41
Current ratio
12.159.4717.096.288.85
Interest coverage
-31.8-32.7941.56-12.23-6.81
Income quality
0.791.080.871.140.47
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
13.013.260.271.8613.56
Intangibles to total assets
0.010.010.110.120.1
Capex to operating cash flow
0.070.07-0.060.120.05
Capex to revenue
-0.91-0.25-0.03-0.17-0.45
Capex to depreciation
-1-0.89-2.39-2.07-0.6
Stock based compensation to revenue
2.410.580.050.322.22
Graham number
24.1218.6345.7124.9325.18
ROIC
-0.29-0.320.4-0.21-0.74
Return on tangible assets
-0.29-0.370.46-0.2-0.41
Graham Net
6.383.58.534.370.06
Working capital
352.58M231.58M591.48M400.86M578.18M
Tangible asset value
317.14M240M505.46M391.65M120.81M
Net current asset value
258.63M162.42M414.84M247.82M27.83M
Invested capital
0.230.290.230.30.67
Average receivables
590K3.78M32.69M80.57M53.28M
Average payables
4.74M4.73M3.14M6.74M8.79M
Average inventory
2.92M4.53M7.44M8.73M9.47M
Days sales outstanding
47.4764.3940.94350.9296.6
Days payables outstanding
21.8911.2536.561.2K176.39
Days of inventory on hand
18.1812.93154.03755.99322.04
Receivables turnover
7.695.678.921.043.78
Payables turnover
16.6832.459.980.32.07
Inventory turnover
20.0828.222.370.481.13
ROE
-0.4-0.510.55-0.27-1.49
Capex per share
-0.17-0.21-0.38-0.38-0.15

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
2.190.110.050.030.14
Net income per share
0.14-1.63-1.44-1.88-1.53
Operating cash flow per share
-1.16-1.65-1.20.81-1.04
Free cash flow per share
-1.27-1.7-1.220.78-1.08
Cash per share
7.516.6513.1913.7912.92
Book value per share
10.138.77.415.634.34
Tangible book value per share
8.346.895.623.882.53
Share holders equity per share
10.138.77.415.634.34
Interest debt per share
3.123.073.062.573.22
Market cap
1.06B955.37M546.06M320.54M323.84M
Enterprise value
979.65M943.51M171.55M229.35M220.88M
P/E ratio
39.11-3.09-1.99-0.89-1.11
Price to sales ratio
10.36179.41225.46227.8248.41
POCF ratio
-19.47-12.2-9.588.24-6.54
PFCF ratio
-17.82-11.85-9.48.61-6.28
P/B Ratio
2.242.311.551.191.56
PTB ratio
2.242.311.551.191.56
EV to sales
9.53177.1970.83163.0133.02
Enterprise value over EBITDA
34.15-13.48-2.9-2.8-4.38
EV to operating cash flow
-17.92-12.05-3.015.89-4.46
EV to free cash flow
-16.4-11.7-2.956.16-4.28
Earnings yield
0.01-0.08-0.13-0.28-0.23
Free cash flow yield
-0.06-0.08-0.110.12-0.16
Debt to equity
0.30.340.390.510.67
Debt to assets
0.20.230.150.160.17
Net debt to EBITDA
-2.970.176.321.112.04
Current ratio
6.286.6711.0710.118.85
Interest coverage
7.74-20.82-9.515.3-3.93
Income quality
-8.031.010.83-0.430.68
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.5711.4219.0146.486.37
Intangibles to total assets
0.120.140.090.10.1
Capex to operating cash flow
0.090.030.02-0.040.04
Capex to revenue
-0.05-0.44-0.44-1.21-0.3
Capex to depreciation
-2.17-0.93-0.41-0.65-0.49
Stock based compensation to revenue
0.121.513.677.891.05
Graham number
5.7517.8515.4815.4112.23
ROIC
0.04-0.12-0.12-0.18-0.17
Return on tangible assets
0.01-0.14-0.08-0.11-0.1
Graham Net
4.353.782.541.360.06
Working capital
400.86M376.31M688.6M625.02M578.18M
Tangible asset value
391.65M327.07M267.59M185.54M120.81M
Net current asset value
247.82M224.41M167.51M90.86M27.83M
Invested capital
0.30.340.390.510.67
Average receivables
52.99M103.58M103.68M52.1M2.92M
Average payables
9.28M9.93M9.13M7.48M6.09M
Average inventory
5.5M7.2M8.84M12.93M13.84M
Days sales outstanding
89.681.77K3.81K105.1656.42
Days payables outstanding
599.13328.4623.94499.5667.09
Days of inventory on hand
377.67276.36679.791.4K122.49
Receivables turnover
10.050.020.861.6
Payables turnover
0.150.270.140.181.34
Inventory turnover
0.240.330.130.060.73
ROE
0.01-0.19-0.19-0.33-0.35
Capex per share
-0.11-0.05-0.02-0.04-0.04

QURE Frequently Asked Questions

What is uniQure N.V. stock symbol ?

uniQure N.V. is a NL stock and trading under the symbol QURE

Is uniQure N.V. buy or a sell ?

6 stock analysts have 6 predictions with a medium analyst target price of $53.67. The lowest prediction is $34 and the highest is $62

What is QURE stock prediction ?

What is uniQure N.V. stock quote today ?

uniQure N.V. stock price is $4.725 today.

Is uniQure N.V. stock public?

Yes, uniQure N.V. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap